Cargando…
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and with specific fluorodeoxyglucose positron emission tomography (FDG-PET) r...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979764/ https://www.ncbi.nlm.nih.gov/pubmed/36806558 http://dx.doi.org/10.1182/bloodadvances.2022007825 |
_version_ | 1784899782414696448 |
---|---|
author | Mazzara, Saveria Travaini, Laura Botta, Francesca Granata, Chiara Motta, Giovanna Melle, Federica Fiori, Stefano Tabanelli, Valentina Vanazzi, Anna Ramadan, Safaa Radice, Tommaso Raimondi, Sara Lo Presti, Giuliana Ferrari, Mahila E. Jereczek-Fossa, Barbara Alicja Tarella, Corrado Ceci, Francesco Pileri, Stefano Derenzini, Enrico |
author_facet | Mazzara, Saveria Travaini, Laura Botta, Francesca Granata, Chiara Motta, Giovanna Melle, Federica Fiori, Stefano Tabanelli, Valentina Vanazzi, Anna Ramadan, Safaa Radice, Tommaso Raimondi, Sara Lo Presti, Giuliana Ferrari, Mahila E. Jereczek-Fossa, Barbara Alicja Tarella, Corrado Ceci, Francesco Pileri, Stefano Derenzini, Enrico |
author_sort | Mazzara, Saveria |
collection | PubMed |
description | Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and with specific fluorodeoxyglucose positron emission tomography (FDG-PET) radiomic profiles in diffuse large B-cell lymphoma (DLBCL). We retrospectively analyzed a discovery cohort of 48 consecutive patients with DLBCL treated at our center with standard first-line chemoimmunotherapy by performing targeted GEP (T-GEP)– and FDG-PET radiomic analyses on the same target lesions at baseline. T-GEP–based metabolic profiling identified a 6-gene signature independently associated with outcomes in univariate and multivariate analyses. This signature included genes regulating mitochondrial oxidative metabolism (SCL25A1, PDK4, PDPR) that were upregulated and was inversely associated with genes involved in hypoxia and glycolysis (MAP2K1, HIF1A, GBE1) that were downregulated. These data were validated in 2 large publicly available cohorts. By integrating FDG-PET radiomics and T-GEP, we identified a radiometabolic signature (RadSig) including 4 radiomic features (histo kurtosis, histo energy, shape sphericity, and neighboring gray level dependence matrix contrast), significantly associated with the metabolic GEP–based signature (r = 0.43, P = .0027) and with progression-free survival (P = .028). These results were confirmed using different target lesions, an alternative segmentation method, and were validated in an independent cohort of 64 patients. RadSig retained independent prognostic value in relation to the International Prognostic Index score and metabolic tumor volume (MTV). Integration of RadSig and MTV further refined prognostic stratification. This study provides the proof of principle for the use of FDG-PET radiomics as a tool for noninvasive assessment of cancer metabolism and prognostic stratification in DLBCL. |
format | Online Article Text |
id | pubmed-9979764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-99797642023-03-03 Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL Mazzara, Saveria Travaini, Laura Botta, Francesca Granata, Chiara Motta, Giovanna Melle, Federica Fiori, Stefano Tabanelli, Valentina Vanazzi, Anna Ramadan, Safaa Radice, Tommaso Raimondi, Sara Lo Presti, Giuliana Ferrari, Mahila E. Jereczek-Fossa, Barbara Alicja Tarella, Corrado Ceci, Francesco Pileri, Stefano Derenzini, Enrico Blood Adv Lymphoid Neoplasia Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and with specific fluorodeoxyglucose positron emission tomography (FDG-PET) radiomic profiles in diffuse large B-cell lymphoma (DLBCL). We retrospectively analyzed a discovery cohort of 48 consecutive patients with DLBCL treated at our center with standard first-line chemoimmunotherapy by performing targeted GEP (T-GEP)– and FDG-PET radiomic analyses on the same target lesions at baseline. T-GEP–based metabolic profiling identified a 6-gene signature independently associated with outcomes in univariate and multivariate analyses. This signature included genes regulating mitochondrial oxidative metabolism (SCL25A1, PDK4, PDPR) that were upregulated and was inversely associated with genes involved in hypoxia and glycolysis (MAP2K1, HIF1A, GBE1) that were downregulated. These data were validated in 2 large publicly available cohorts. By integrating FDG-PET radiomics and T-GEP, we identified a radiometabolic signature (RadSig) including 4 radiomic features (histo kurtosis, histo energy, shape sphericity, and neighboring gray level dependence matrix contrast), significantly associated with the metabolic GEP–based signature (r = 0.43, P = .0027) and with progression-free survival (P = .028). These results were confirmed using different target lesions, an alternative segmentation method, and were validated in an independent cohort of 64 patients. RadSig retained independent prognostic value in relation to the International Prognostic Index score and metabolic tumor volume (MTV). Integration of RadSig and MTV further refined prognostic stratification. This study provides the proof of principle for the use of FDG-PET radiomics as a tool for noninvasive assessment of cancer metabolism and prognostic stratification in DLBCL. The American Society of Hematology 2022-09-19 /pmc/articles/PMC9979764/ /pubmed/36806558 http://dx.doi.org/10.1182/bloodadvances.2022007825 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Lymphoid Neoplasia Mazzara, Saveria Travaini, Laura Botta, Francesca Granata, Chiara Motta, Giovanna Melle, Federica Fiori, Stefano Tabanelli, Valentina Vanazzi, Anna Ramadan, Safaa Radice, Tommaso Raimondi, Sara Lo Presti, Giuliana Ferrari, Mahila E. Jereczek-Fossa, Barbara Alicja Tarella, Corrado Ceci, Francesco Pileri, Stefano Derenzini, Enrico Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title | Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title_full | Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title_fullStr | Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title_full_unstemmed | Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title_short | Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL |
title_sort | gene expression profiling and fdg-pet radiomics uncover radiometabolic signatures associated with outcome in dlbcl |
topic | Lymphoid Neoplasia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979764/ https://www.ncbi.nlm.nih.gov/pubmed/36806558 http://dx.doi.org/10.1182/bloodadvances.2022007825 |
work_keys_str_mv | AT mazzarasaveria geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT travainilaura geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT bottafrancesca geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT granatachiara geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT mottagiovanna geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT mellefederica geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT fioristefano geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT tabanellivalentina geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT vanazzianna geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT ramadansafaa geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT radicetommaso geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT raimondisara geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT loprestigiuliana geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT ferrarimahilae geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT jereczekfossabarbaraalicja geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT tarellacorrado geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT cecifrancesco geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT pileristefano geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl AT derenzinienrico geneexpressionprofilingandfdgpetradiomicsuncoverradiometabolicsignaturesassociatedwithoutcomeindlbcl |